Vernalis and Servier reach first oncology milestone
This article was originally published in Scrip
Executive Summary
Vernalisand the privately held French pharmaceutical company Servierhave achieved the first milestone in their three-year oncology drug discovery collaboration that was signed in May last year. The milestone, which will see Servier pay Vernalis $500,000, marks the solving of the novel crystal structure of an undisclosed oncology target. As part of the joint research programme Servier funds Vernalis's scientists and applies Vernalis's structure-based discovery capabilities to two oncology targets involved in protein-protein interactions.
You may also be interested in...
Myotec and Hybrid merge to form PsiOxus
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
Trophos's MitoCare programme receives €6 million EU funding
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Novartis and Alcon reach compromise to settle merger saga
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.